Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer

Homologous recombination (HR) is a highly conserved DNA repair system, in which aberrations can lead to the accumulation of DNA damage and genomic scars known as homologous recombination deficiency (HRD). The identification of mutations in key genes (i.e., BRCA1, and BRCA2 (BRCA)) and the quantifica...

Cijeli opis

Bibliografski detalji

Glavni autori:	Qianying Zhao, Liping Bai, Yu Tan, Mingrong Qie
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-07-01
Serija:	Frontiers in Oncology
Teme:	homologous recombination (HR) PARP inhibitor (PARPi) ovarian cancer (OC) future prospect limitations
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1435029/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!